Split-face studies tell us that acne treatments work—and they do so more reliably than we might expect. By treating one side of a patient’s face while leaving the other side untreated as a control, researchers can definitively prove that improvements in acne come directly from the treatment itself, not from placebo effects, natural healing, or daily skincare routines. This methodology eliminates the biggest source of uncertainty in acne research: whether the person got better because of the treatment or for some other reason entirely. For instance, a recent split-face trial comparing a novel three-step skincare routine (containing azelaic acid, salicylic acid, and graduated retinol) against over-the-counter benzoyl peroxide showed which approach actually performed better on the same person—something that would be impossible to determine fairly in a conventional trial.
This article explores what split-face studies reveal about how well different acne treatments work, why dermatologists trust these findings, and what you should know before choosing your own acne therapy. Split-face studies have become the gold standard for proving acne treatment effectiveness because they address a fundamental problem in acne research: acne varies dramatically from person to person, and even on different parts of the same face. A standard trial that treats one group of people and compares them to another group will always have this nagging doubt: maybe the treated group had milder acne to begin with, or better genetics, or a luckier microbiome. Split-face designs eliminate that doubt by making each patient their own control. The untreated side of the face serves as a built-in comparison, showing exactly what would have happened without treatment on that individual’s skin.
Table of Contents
- How Split-Face Studies Control for Individual Variation in Acne
- What Split-Face Studies Reveal About Treatment Effectiveness—and Their Limitations
- Real Clinical Evidence from Recent Acne Treatment Trials
- Why Dermatologists Prioritize Split-Face Evidence When Recommending Treatments
- What Split-Face Studies Reveal About Different Acne Treatment Modalities
- How Assessment Methods in Split-Face Studies Ensure Accurate Results
- The Future of Acne Treatment Evidence and Split-Face Study Design
- Conclusion
- Frequently Asked Questions
How Split-Face Studies Control for Individual Variation in Acne
The core strength of split-face methodology lies in its ability to isolate the treatment effect from everything else that influences acne. When researchers assess acne severity, they use standardized metrics like the Acne Severity Index (ASI) and serial blinded lesion counts—meaning the doctors counting pimples don’t know which side was treated, eliminating observer bias. The untreated side develops naturally over the study period, and because it’s the same person, with the same genetics, diet, stress levels, and bacteria, any difference between sides must come from the treatment. This is mathematically more powerful than comparing two different groups of people, which is why split-face trials can often prove effectiveness with smaller sample sizes than conventional studies.
Consider a 2020 split-face trial comparing fractional microneedle radiofrequency (a newer technique that combines microneedling with radiofrequency energy) against standard fractional radiofrequency. In just 10 patients over 24 weeks, researchers could clearly show that the microneedle version produced superior results after the first treatment and generated higher patient satisfaction scores on the treated side. With only 10 people, a conventional trial couldn’t reliably prove anything—but a split-face design could, because each patient provided two data points: one treated side and one control side. The comparison was happening on the same face, under the same conditions, with the same biology.
What Split-Face Studies Reveal About Treatment Effectiveness—and Their Limitations
Split-face studies provide remarkably clear evidence about whether treatments work, but they come with a crucial caveat: they measure short-term improvement over weeks or months, not long-term acne prevention or maintenance. Most of the clinical trials showing effectiveness—from cold atmospheric plasma treatments to photopneumatic therapy—track patients for 8 to 24 weeks. We see that inflammatory lesions drop by 30% to 52%, that improvements persist at follow-up visits, and that patients prefer the treated side. However, if you stop the treatment, the acne will typically return.
Split-face studies are excellent at answering the question “Does this work right now?” but less useful for questions like “Will this prevent acne long-term?” or “Is this better than just living with acne?” Another limitation is that split-face studies often exclude certain skin types or severity levels. A 2026 dermocosmetic study specifically assessed treatments in patients with fair skin phototypes, which tells us nothing about how those treatments perform on darker skin. Similarly, most trials focus on mild-to-moderate acne; someone with severe cystic acne affecting the entire face might not benefit from a comparison between two treated sides. Additionally, split-face design assumes the condition doesn’t spread from one side to the other or that treating one side won’t somehow affect the untreated side through systemic effects—a reasonable assumption for topical treatments but less certain for oral medications or therapies that might have whole-body effects. If you’re considering an acne treatment, split-face evidence is compelling proof it works, but it’s not the whole story about whether it’s right for you.
Real Clinical Evidence from Recent Acne Treatment Trials
The past few years have produced an impressive body of split-face evidence on a variety of treatments. Cold atmospheric plasma treatment, a technology that uses ionized gas to target acne-causing bacteria, showed a 30% reduction in inflammatory lesions by the end of treatment, which improved further to 44% at a two-week follow-up and 52% at four weeks. This isn’t a minor improvement—a 52% reduction in active breakouts represents a dramatically clearer complexion. The fact that improvements continued even after treatment ended (at the two-week and four-week follow-ups) suggests the treatment may trigger longer-lasting changes in skin bacteria or inflammation.
Photopneumatic therapy, an older but well-documented approach combining light and pneumatic energy, produced similarly impressive results in a study of 20 adults with mild-to-moderate acne. Patients received four treatments over eight weeks, and significant improvements in inflammatory lesions persisted all the way through a 12-week final follow-up—meaning the treatment effect lasted months after the therapy ended. In contrast, the 2024 trial comparing a novel three-step skincare routine (azelaic acid, salicylic acid, and graduated retinol) against benzoyl peroxide involved 37 adult subjects and ran for 12 weeks. Both approaches worked, but the study clarified which worked better and for whom, allowing dermatologists to make evidence-based recommendations. These real-world results matter because they show that multiple different treatment approaches—devices, topical medications, and combination regimens—can produce meaningful acne improvements when studied rigorously.
Why Dermatologists Prioritize Split-Face Evidence When Recommending Treatments
When your dermatologist suggests a particular acne treatment, there’s a good chance that recommendation is backed by split-face trial data because this study design is simply more convincing than alternatives. A dermatologist comparing two potential treatments for you needs to know which one actually works better, not just that both work in general. Split-face studies provide that direct comparison on the same person, which is infinitely more useful than reading that treatment A helped 70% of people in one trial and treatment B helped 65% of people in another trial (where the groups might have had different skin types, different acne severity, or different baseline conditions). The elimination of individual variation bias also means dermatologists can trust the results more confidently.
A patient with severe acne and oily skin might see their skin improve anyway just from better skincare habits or natural clearing—but a split-face study removes that uncertainty. If the untreated side didn’t improve but the treated side did, the improvement definitively came from the treatment. This is why newer therapies like fractional microneedle radiofrequency and cold atmospheric plasma can gain acceptance relatively quickly: split-face evidence is so powerful that a well-designed trial with even a modest sample size can convince dermatologists of efficacy. For you as a patient, this means when your dermatologist pulls out a split-face study to support their recommendation, they’re using the strongest type of evidence available in acne research.
What Split-Face Studies Reveal About Different Acne Treatment Modalities
Split-face studies have been applied to an surprisingly diverse range of acne treatments, from topical pharmaceuticals to energy-based devices to combination regimens. This breadth of evidence helps illustrate that acne treatment effectiveness is not one-size-fits-all. Topical treatments like the three-step routine combining azelaic acid, salicylic acid, and retinol work through different mechanisms than device-based approaches like radiofrequency, which works differently again from phototherapy. Yet all of these have solid split-face evidence supporting their effectiveness. The variation in results across studies also highlights an important limitation: a treatment that works brilliantly for one person (as evidenced by the treated side of their face) might work less well for someone else.
The split-face design proves the treatment *can* work, but it doesn’t guarantee it *will* work for you. One warning worth emphasizing: split-face studies measure improvement compared to the untreated side, not compared to baseline severity. This means a treatment might produce a measurable reduction in lesion counts while still leaving someone with noticeable acne. If you have severe acne, a 30% to 50% reduction might still leave you with plenty of visible breakouts. Additionally, many split-face trials exclude patients taking oral medications like isotretinoin or systemic antibiotics, so if you’re on those treatments, the study evidence may not fully apply to your situation. The evidence tells you the treatment works within the study parameters, not necessarily that it’s sufficient for your particular acne.
How Assessment Methods in Split-Face Studies Ensure Accurate Results
The rigor of split-face studies depends heavily on how acne severity is actually measured. Most modern split-face trials use multiple assessment methods simultaneously: blinded lesion counts (counting individual pimples without knowing which side was treated), global acne severity ratings (an overall assessment), and often photography so changes can be documented visually. The Acne Severity Index (ASI) and similar standardized metrics allow comparisons across different studies—if one trial reports a 44% reduction at two-week follow-up, you know that number was calculated using the same method as other trials reporting similar metrics. This standardization is what makes split-face evidence so powerful: results from a 2024 trial in one country can be directly compared to results from a 2022 trial elsewhere because they’re using comparable measurement approaches. The blinding aspect deserves special mention.
When the dermatologist or researcher assessing the skin doesn’t know which side was treated, they can’t unconsciously bias their assessment toward expecting the treated side to look better. They count lesions on both sides without knowing which is which, and only afterward is the blinding removed. This simple precaution eliminates one of the sneakiest sources of bias in medical research—observer expectation. For example, a researcher who knows one side was treated with an expensive new device might unconsciously count fewer lesions on that side simply because they expect improvement. Blinding prevents this and ensures the measurements reflect actual skin changes, not expectations.
The Future of Acne Treatment Evidence and Split-Face Study Design
As acne treatments continue to evolve—with emerging technologies like energy-based devices becoming more sophisticated and skincare formulations becoming more complex—split-face studies will remain the gold standard for proving efficacy. The fact that researchers are still using this methodology in 2026 (as evidenced by recent dermocosmetic studies) shows its continued relevance. However, the field is also recognizing limitations and developing complementary approaches: some trials now include multiple assessment methods, longer follow-up periods, and evaluation across different skin types and phototypes rather than just fair-skinned populations. Future split-face studies will likely need to address diversity more systematically.
Most existing split-face evidence comes from studies that either didn’t report skin types or focused on fair skin. As the field recognizes this gap, we should expect more split-face trials explicitly including darker skin phototypes, which may react differently to treatments. Additionally, combination therapies (like topical treatments plus devices) are becoming more common, and split-face designs are perfectly suited to testing whether combinations outperform single treatments. For anyone evaluating acne treatment options, split-face evidence will likely remain the most trustworthy type of clinical data available.
Conclusion
Split-face studies tell us that acne treatments work, they work in measurable and meaningful ways, and we can know this with confidence because each patient serves as their own control. The methodology eliminates individual variation bias, reduces observer bias through blinding, and produces more reliable results than conventional trial designs. Whether the treatment is a topical regimen, a device-based therapy, or a newer technology like cold atmospheric plasma, split-face evidence provides clear proof that improvements in acne come directly from the treatment, not from placebo effects or natural clearing.
When considering any acne treatment—especially newer or more expensive options—look for split-face trial data to back the claims. The fact that a treatment worked for 30%, 44%, or 52% of people in a study matters far less than whether that improvement came from the treatment itself, which is precisely what split-face design proves. Ask your dermatologist whether the treatment they’re recommending has split-face evidence supporting it, and if so, ask what the specific results were in those trials. That conversation will give you the clearest possible picture of what you can expect.
Frequently Asked Questions
Why is a split-face study better than treating one group and comparing to an untreated group?
A split-face study eliminates individual variation bias. Two different people will always have different genetics, skin microbiomes, and acne severity—making it impossible to know if differences in outcomes came from the treatment or from differences between the people. By treating one side of the same person’s face and leaving the other untreated, researchers ensure any difference between sides comes from the treatment, not from individual variation.
Can the untreated side of my face somehow be affected by treating the other side?
For topical treatments, this is extremely unlikely—the medication stays on the side where you apply it. For systemic treatments or therapies with whole-body effects, there could theoretically be some spillover, which is one reason most split-face studies use topical treatments or localized devices. If you’re considering a treatment that might affect your whole body (like oral medication), conventional trial data may be more relevant than split-face evidence.
If a treatment showed a 30% reduction in acne, does that mean my acne will improve by 30%?
Not necessarily. The 30% reduction was measured on the untreated side of the study subjects’ faces—it’s a relative improvement, not an absolute guarantee for you. Your baseline acne severity, skin type, and individual factors will influence how much you improve. Additionally, if you have severe acne, a 30% reduction might still leave you with significant breakouts. Split-face evidence proves the treatment *can* work, but not how much it will help you specifically.
How long do split-face study results last after treatment stops?
Most split-face trials show results for a few weeks to a few months after treatment ends. For example, cold atmospheric plasma treatment showed 44% improvement two weeks after treatment and 52% improvement four weeks out. However, most split-face trials don’t track patients for years, so we don’t know about long-term maintenance. If you need ongoing acne control, you’ll likely need ongoing treatment.
Are split-face studies done for all types of acne treatments?
Not exclusively—some treatments are tested using conventional trial designs. However, split-face designs are particularly valuable for acne because they’re so powerful at proving efficacy. Newer treatments and device-based therapies especially tend to be evaluated with split-face trials because they provide such clear evidence. If a split-face trial exists for your treatment, it’s a strong sign of efficacy.
Can split-face study results apply to me if I have severe acne or a different skin type than the study subjects?
Maybe partially. Split-face trials typically focus on mild-to-moderate acne and often don’t report results broken down by skin type. A treatment that worked on fair skin in a trial might work differently on darker skin, and treatment that improved mild acne might not be sufficient for severe cases. Always ask your dermatologist whether the specific trial evidence applies to your situation.
